Polli F, Savioli M, Cugno M, Taccone P, Bellani G, Spanu P, Pesenti A, Iapichino G, Gattinoni L
Institute of Anesthesia and Intensive Care, University of Milan, Milan, Italy.
Minerva Anestesiol. 2009 Jul-Aug;75(7-8):417-26. Epub 2008 Jan 24.
Recombinant human activated protein C (rh-APC) and tight glycemic control (TGC) have been shown to reduce mortality in septic patients. Both interventions can reduce the plasma concentration and/or activity of the most powerful suppressor of fibrinolysis, plasminogen activator inhibitor-1 (PAI-1). Our aim was to evaluate the effects on the fibrinolytic system after the administration of rh-APC in septic patients undergoing conventional or TGC.
Posthoc analysis of data was collected from 90 patients with severe sepsis/septic shock, randomized to either conventional or TGC groups. Independent of these treatments, patients with at least two organ dysfunctions simultaneously received rh-APC. Plasma levels of multiple biochemical markers for fibrinolysis, coagulation, and inflammation were determined every day for the 1st week and then on study days 9, 11, 13, 18, 23, and 28. Clinical data and sepsis-related organ failure assessment (SOFA) scores were also recorded.
Patients who had received rh-APC exhibited significantly more impairments in fibrinolysis at baseline (PAI-1 activity 49.76 [24.61-71.82] vs 21.92 [6.47-55-83] IU/mL, P=0.03). The reductions in plasma PAI-1 activity over time associated with rh-APC treatment were different according to whether the treatment was administered to patients undergoing conventional or TGC (P=0.01). However, the most prominent reductions were in patients undergoing conventional glycemic control. Significant interactions between the two study interventions were also found for PAI-1 concentration (P<0.001), C-reactive protein (P=0.02), and interleukin-6 levels (P<0.001).
Both rh-APC and TGC appear to improve fibrinolysis in septic patients. The reduction in the impairment of fibrinolysis associated with rh-APC treatment seems greater in patients undergoing conventional glycemic control than in those undergoing TGC.
重组人活化蛋白C(rh-APC)和严格血糖控制(TGC)已被证明可降低脓毒症患者的死亡率。这两种干预措施均可降低纤溶酶原激活物抑制剂-1(PAI-1)的血浆浓度和/或活性,PAI-1是最强大的纤维蛋白溶解抑制剂。我们的目的是评估rh-APC对接受传统治疗或TGC的脓毒症患者纤溶系统的影响。
对90例严重脓毒症/脓毒性休克患者的数据进行事后分析,这些患者被随机分为传统治疗组或TGC组。独立于这些治疗,至少有两个器官功能障碍的患者同时接受rh-APC治疗。在第1周每天测定纤溶、凝血和炎症的多种生化标志物的血浆水平,然后在研究的第9、11、13、18、23和28天测定。还记录了临床数据和脓毒症相关器官功能衰竭评估(SOFA)评分。
接受rh-APC治疗的患者在基线时纤溶功能障碍明显更多(PAI-1活性为49.76[24.61-71.82]vs 21.92[6.47-55.83]IU/mL,P=0.03)。根据rh-APC治疗是给予接受传统治疗还是TGC的患者,血浆PAI-1活性随时间的降低情况有所不同(P=0.01)。然而,最显著的降低发生在接受传统血糖控制的患者中。在PAI-1浓度(P<0.001)、C反应蛋白(P=0.02)和白细胞介素-6水平(P<0.001)方面,还发现了两种研究干预措施之间的显著相互作用。
rh-APC和TGC似乎都能改善脓毒症患者的纤溶功能。与rh-APC治疗相关的纤溶功能障碍的减轻在接受传统血糖控制的患者中似乎比在接受TGC的患者中更大。